BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

CHMP gives nod for Sanofi’s Cenrifki for multiple sclerosis
Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA...

More in BioWorld

BioWorld Science

Detecting the invisible: minimal residual disease at AACR 2026
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision. As...

More in BioWorld Science

A closer look

Med-tech financings steady at $8.8B in Q1, despite volume drop
Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent...

More in A closer look

BioWorld Asia

Biogen amasses full felzartamab rights with $850M TJ deal
Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.